NASDAQ:NRXP NRx Pharmaceuticals (NRXP) Stock Price, News & Analysis → After Conviction, More Bad News for Trump (From Paradigm Press) (Ad) Free NRXP Stock Alerts $3.21 -0.19 (-5.59%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$3.20▼$3.4050-Day Range$2.06▼$52.5052-Week Range$1.90▼$7.33Volume95,467 shsAverage Volume231,184 shsMarket Capitalization$34.35 millionP/E RatioN/ADividend YieldN/APrice Target$43.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NRx Pharmaceuticals alerts: Email Address NRx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,239.6% Upside$43.00 Price TargetShort InterestBearish7.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-1.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.85 out of 5 starsMedical Sector782nd out of 904 stocksPharmaceutical Preparations Industry368th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingNRx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNRx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about NRx Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.00% of the float of NRx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNRx Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NRx Pharmaceuticals has recently increased by 0.35%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNRx Pharmaceuticals does not currently pay a dividend.Dividend GrowthNRx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRXP. Previous Next 0.6 News and Social Media Coverage News SentimentNRx Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for NRx Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NRXP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NRx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders21.06% of the stock of NRx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.27% of the stock of NRx Pharmaceuticals is held by institutions.Read more about NRx Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of NRx Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NRx Pharmaceuticals is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NRx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAfter Conviction, More Bad News for TrumpAs a former advisor to the CIA, the Pentagon and the White House… I feel it’s my duty to warn you about this coming election meltdown.Click here to see the details because this coming election meltdown could trigger… About NRx Pharmaceuticals Stock (NASDAQ:NRXP)NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Read More NRXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXP Stock News HeadlinesJune 8 at 6:21 AM | americanbankingnews.comNRx Pharmaceuticals (NASDAQ:NRXP) Given New $43.00 Price Target at Ascendiant Capital MarketsMay 28, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Presents Landmark Trial of NRX-101 in Suicidal Bipolar Depression At the American Society of Clinical Psychopharmacology Annual Meeting: NRX-101 is the First Oral Antidepressant Demonstrated to Reduce Suicidality in Bipolar DepressionMay 19, 2024 | msn.comNRx Pharmaceuticals Holds Promise for Investors and Patients AlikeMay 15, 2024 | msn.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finanznachrichten.deNRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 15, 2024 | finance.yahoo.comNRX Pharmaceuticals Inc (NRXP) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comNRXP Stock Earnings: NRX Pharmaceuticals Misses EPS for Q1 2024May 14, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 13, 2024 | msn.comNRx Pharmaceuticals to Unveil First Quarter Financial Results and Corporate UpdateMay 13, 2024 | msn.comNRx Pharmaceuticals Makes Significant Stride with New Depression Drug, Aims for Accelerated FDA ApprovalMay 8, 2024 | markets.businessinsider.comNRx Pharmaceuticals Eyes First Commercial Revenue in 2024, Announces Breakthroughs in Bi-Annual Milestone UpdateMay 8, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024May 7, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024May 6, 2024 | marketwatch.comNRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial DataMay 6, 2024 | markets.businessinsider.comNRx Pharmaceuticals Plans To Seek Accelerated Approval Of NRX-101 - Quick FactsMay 6, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar DepressionApril 30, 2024 | prnewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar DepressionApril 18, 2024 | investorplace.comWhy Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today?April 18, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 18, 2024 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price RequirementApril 18, 2024 | prnewswire.comNRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common StockApril 17, 2024 | markets.businessinsider.comNRx Pharmaceuticals: New Data Demonstrates No Impact Of NRX-101 On Gut Or Vaginal FloraApril 17, 2024 | finance.yahoo.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infectionsApril 15, 2024 | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)See More Headlines Receive NRXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NRXP CUSIPN/A CIK1719406 Webwww.bigrockpartners.com Phone(484) 254-6134FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$43.00 High Stock Price Target$43.00 Low Stock Price Target$43.00 Potential Upside/Downside+1,239.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-260.31% Debt Debt-to-Equity RatioN/A Current Ratio0.18 Quick Ratio0.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.38) per share Price / Book-2.33Miscellaneous Outstanding Shares10,700,000Free Float8,447,000Market Cap$34.35 million OptionableOptionable Beta1.29 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jonathan C. Javitt M.D. (Age 67)M.P.H., Co-Founder, Chief Scientist Officer & Chairman Comp: $873.7kMr. Stephen H. Willard Esq. (Age 63)Acting Corporate Secretary, CEO & Director Comp: $501.19kDr. Riccardo Panicucci Ph.D. (Age 62)Chief Technology Officer Comp: $240kDr. Seth L. Van Voorhees Ph.D. (Age 63)Treasurer Comp: $399.96kMr. Richard Clavano Narido (Age 46)Interim CFO, Principal Financial Officer & Principal Accounting Officer Suzanne MessereInvestor RelationsDr. Philip T. Lavin Ph.D. (Age 77)Chief Methodologist Dr. Dennis K. McBride Ph.D.Chief Strategy Officer & Senior ScientistMr. Matthew Patrick Duffy (Age 61)Chief Business Officer More ExecutivesKey CompetitorsHall of Fame Resort & EntertainmentNASDAQ:HOFVMomentusNASDAQ:MNTSRepare TherapeuticsNASDAQ:RPTXVeruNASDAQ:VERUscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInsidersAaron GorovitzBought 3,500 shares on 8/30/2023Total: $11,200.00 ($3.20/share)Jonathan C JavittBought 20,000 shares on 8/22/2023Total: $64,000.00 ($3.20/share)View All Insider Transactions NRXP Stock Analysis - Frequently Asked Questions Should I buy or sell NRx Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NRx Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NRXP shares. View NRXP analyst ratings or view top-rated stocks. What is NRx Pharmaceuticals' stock price target for 2024? 1 brokerages have issued 12 month price objectives for NRx Pharmaceuticals' stock. Their NRXP share price targets range from $43.00 to $43.00. On average, they anticipate the company's share price to reach $43.00 in the next year. This suggests a possible upside of 1,239.6% from the stock's current price. View analysts price targets for NRXP or view top-rated stocks among Wall Street analysts. How have NRXP shares performed in 2024? NRx Pharmaceuticals' stock was trading at $46.00 at the beginning of the year. Since then, NRXP shares have decreased by 93.0% and is now trading at $3.21. View the best growth stocks for 2024 here. When is NRx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our NRXP earnings forecast. How were NRx Pharmaceuticals' earnings last quarter? NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.74) earnings per share for the quarter. What ETF holds NRx Pharmaceuticals' stock? AdvisorShares Psychedelics ETF holds 95,043 shares of NRXP stock, representing 5.35% of its portfolio. When did NRx Pharmaceuticals' stock split? Shares of NRx Pharmaceuticals reverse split on the morning of Tuesday, April 2nd 2024. The 1-10 reverse split was announced on Tuesday, April 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has NRx Pharmaceuticals issued on next quarter's earnings? NRx Pharmaceuticals issued an update on its FY 2023 earnings guidance on Thursday, March, 28th. The company provided earnings per share (EPS) guidance of -0.400--0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -. How do I buy shares of NRx Pharmaceuticals? Shares of NRXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NRXP) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
